← Back
Data updated: Jun 28, 2026
LINDE NORTH AMERICA INC
Pharma Pharmaceuticals
LINDE NORTH AMERICA INC is a pharmaceutical company with 4 FDA-approved products.
2013
Since
4
Drugs
-
Trials
8
New Drugs (2yr)
Modality:
4 Small Molecules
LINDE NORTH AMERICA INC's Key Drugs
LINDE NORTH AMERICA INC's core commercial portfolio centers on CARBON DIOXIDE, USP, OXYGEN, USP, NITROGEN, NF — its most strategically important drugs approved in the last 15 years.
LINDE NORTH AMERICA INC's Recent FDA Approvals
LINDE NORTH AMERICA INC secured 8 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
MEDICAL AIR, USP NDA
2026-02-17 CARBON DIOXIDE, USP NDA
2025-10-25 carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16 carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21 carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02 carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09 carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10 carbon dioxide
MEDICAL AIR, USP NDA
2024-07-13 medical air
LINDE NORTH AMERICA INC's Therapeutic Areas
Disease areas where LINDE NORTH AMERICA INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
LINDE NORTH AMERICA INC Pipeline Snapshot
Active clinical trials for LINDE NORTH AMERICA INC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CARBON DIOXIDE, USP leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2013-07-05
- Latest
- 2013-07-05
- Applications
- 5